

16 June 2017

July 2017 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **July 2017** Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

New listings

- Bendamustine hydrochloride (Ribomustin) inj 25 mg vial (p'code 2483807), inj 100 mg vial (p'code 2483793) and (Baxter) inj for ECP (p'code 2524058) – PCT only – Specialist – Special Authority
- Clonidine (Mylan) patch 2.5 mg, 100 mcg per day (p'code 2523078), 5 mg, 200 mcg per day (p'code 2523086) and 7.5 mg, 300 mcg per day (p'code 2523094) – only on a prescription
- Flucloxacillin (Flucil) inj 1 g vial – up to 10 inj available on a PSO (p'code 2523108)
- Haemophilus influenza type B vaccine (Hiberix) Haemophilus influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml – Xpharm (p'code 2087758)
- Lenalidomide (Revlimid) cap 15 mg (p'code 2369478) – Retail pharmacy-Specialist – Special Authority, wastage claimable
- Lidocaine [lignocaine] (LMX4) crm 4%, 5 g OP – Special Authority – Retail pharmacy (p'code 2523248)
- Measles, mumps and rubella vaccine (Priorix) injection, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml – Xpharm (p'code 2509369)
- Melatonin (Circadin) tab modified-release 2 mg – Special Authority – Retail pharmacy, no more than 5 tab per day (p'code 2397692)
- Metoprolol succinate (Betaloc CR) tab long-acting 23.75 mg (p'code 2026945)
- Pharmacy services (BSF Apo-Paroxetine) brand switch fee – may only be claimed once per patient (p'code 2523930)
- Pneumococcal (PCV10) conjugated vaccine (Synflorix) inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe – Xpharm (p'code 2404729)
- Rotavirus oral vaccine (Rotarix) oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator – Xpharm (p'code 2509415)
- Roxithromycin (Rulide D) tab disp 50 mg – restricted to patients under 12 years of age (p'code 2522950)
- Tuberculin [mantoux] test (Tubersol) inj 5 TU per 0.1 ml, 1 ml vial– Xpharm (p'code 703338)
- Varicella vaccine [chickenpox vaccine] (Varilrix) inj 2000 PFU prefilled syringe plus vial– Xpharm (p'code 2514486)

Changes to restrictions, chemical names and presentations

- Antiretrovirals – amended Special Authority criteria
- Azithromycin tab 250 mg and 500 mg (Apo-Azithromycin) and grans for oral liq 200 mg per 5 ml (40 mg per ml) (Zithromax) – Endorsement removed and Special Authority added
- Benzylpenicillin sodium [penicillin G] (Sandoz) inj 600 mg (1 million units) vial – amended chemical presentation

Changes to restrictions, chemical names and presentations (cont)

- Docetaxel (DBL Docetaxel) inj 10 mg per ml, 2 ml and 8 ml vial – amended presentation description
- Enoxaparin sodium (Clexane) inj 20 mg in 0.2 ml, 40 mg in 0.4 ml, 60 mg in 0.6 ml, 80 mg in 0.8 ml, 100 mg in 1 ml, 120 mg in 0.8 ml, 150 mg in 1 ml syringe – amended Special Authority criteria
- Erlotinib (Tarceva) tab 100 mg and 150 mg – amended Special Authority criteria
- Gefitinib (Iressa) tab 250 mg – amended Special Authority criteria
- Hepatitis B recombinant vaccine (HBvaxPRO) inj 5 mcg per 0.5 ml and inj 10 mcg per 1 ml vial – amended restriction
- Influenza vaccine (Influvac) inj 45 mcg in 0.5 ml syringe – amended restriction
- Lamivudine (Zeffix) tab 100 mg and oral liq 5 mg per ml, 240 ml OP – amended Special Authority criteria and addition of OP to oral liquid
- Ledipasvir with sofosbuvir (Harvoni) tab 90 mg with sofosbuvir 400 mg – amended Special Authority criteria
- Meningococcal C conjugate vaccine (Neisvac-C) inj 10 mcg in 0.5 ml syringe – amended chemical name
- Meningococcal (groups A, C, Y and W-135) conjugated vaccine (Menactra) inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial – amended chemical name
- Methotrexate (Methotrexate Ebewe) inj 100 mg per ml, 50 ml vial – amended presentation description
- Midazolam (Pfizer) inj 1 mg per ml, 5 ml and inj 5 mg per ml, 3 ml plastic ampoule – amended presentation description and available on a PSO for status epilepticus use only
- Montelukast (Apo-Montelukast) tab 4 mg, 5 mg and 10 mg – Brand Switch Fee removed
- Nivolumab inj 10 mg per ml, 4 ml vial and 10 ml vial (Opdivo) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Paroxetine (Apo-Paroxetine) tab 20 mg – Brand Switch Fee payable
- Pembrolizumab inj 50 mg vial (Keytruda) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Pethidine hydrochloride (DBL Pethidine Hydrochloride) inj 50 mg per ml, 1 ml and 2 ml ampoule – amended presentation description
- Pneumococcal (PCV13) conjugate vaccine (Prevenar 13) inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe – amended restriction and chemical name
- Pneumococcal (PPV23) polysaccharide vaccine (Pneumovax 23) inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – amended restriction
- Rituximab inj 100 mg per 10 ml, inj 500 mg per 50 ml vial (Mabthera) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Vancomycin (Mylan) inj 500 mg vial – amended presentation description
- Varicella vaccine [chickenpox vaccine] (Varilrix) inj 2000 PFU prefilled syringe plus vial – amended restriction, chemical name and presentation description

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Flucloxacillin	Inj 250 mg and 500 mg vial	Flucloxin
Pamidronate disodium	Inj 6 mg per ml, 10 ml vial	Pamisol

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Amlodipine	Tab 2.5 mg, 5 mg & 10 mg	Apo-Amlodipine	
Amorolfine	Nail soln 5%, 5 ml OP	MycoNail	
Azathioprine	Tab 25 mg & 50 mg	Azamun & Imran*	
Betahistine dihydrochloride	Tab 16 mg	Vergo 16	
Cefazolin	Inj 500 mg & 1 g vial	AFT	
Ciprofloxacin	Tab 250 mg, 500 mg & 750 mg	Ciprox	
Cyproterone acetate with ethinyloestradiol	Tab 2 mg ethinyloestradiol 35 mcg and 7 inert tabs	Ginet	
Docetaxel	Inj 10 mg per ml, 2 ml vial & 8 ml vial	DBL Docetaxel	
Donepezil hydrochloride	Tab 5 mg & 10 mg	Donepezil-Rex	
Doxazosin	Tab 4 mg	Apo-Doxazosin	
Gliclazide	Tab 80 mg	Glizide	
Glycerol	Liquid	healthE Glycerol BP	
Hydrocortisone	Powder	ABM	
Isosorbide mononitrate	Tab long-acting 60 mg	Duride	
Lopinavir with ritonavir	Tab 200 mg with ritonavir 50 mg	Kaletra	
Magnesium sulphate	Inj 2 mmol per ml, 5 ml ampoule	DBL	
Methotrexate	Inj 100 mg per ml, 50 ml vial	Methotrexate Ebewe	
Miconazole nitrate	Vaginal crm 2% with applicator, 40 g OP	Micreme	
Morphine sulphate	Inj 5 mg per ml, inj 10 mg per ml, 15 mg per ml, inj 30 mg per ml, 1 ml ampoules	DBL Morphine Sulphate	
Naltrexone hydrochloride	Tab 50 mg	Naltraccord	
Olanzapine	Tab 2.5 mg, 5 mg & 10 mg	Zypine	
Olanzapine	Tab orodispersible 5 mg & 10 mg	Zypine ODT	
Olopatadine	Eye drops 0.1%, 5 ml OP	Patanol	
Pamidronate disodium	Inj 3 mg per ml & inj 9 mg per ml, 10 ml vial	Pamisol	
Paracetamol with codeine	Tab paracetamol 500 mg with codeine phosphate 8 mg	Paracetamol + Codeine (Relieve)	

Decreased subsidy (cont)

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Pethidine hydrochloride	Inj 50 mg per ml, 1 ml ampoule & 2 ml ampoule	DBL Pethidine Hydrochloride	
Quetiapine	Tab 25 mg, 100 mg, 200 mg & 300 mg	Quetapel	
Risperidone	Oral liq 1 mg per ml, 30 ml	Risperon	
Rizatriptan	Tab orodispersible 10 mg	Rizamelt	
Sodium citro-tartrate	Grans eff 4 g sachet	Ural	
Tramadol hydrochloride	Tab sustained-release 100 mg Tab sustained-release 150 mg Tab sustained-release 200 mg	Tramal SR 100 Tramal SR 150 Tramal SR 200	
Tramadol hydrochloride	Cap 50 mg	Arrow-Tramadol	
Timolol	Eye drops 0.25% & 0.5%, 5 ml OP	Arrow-Timolol	
Ursodeoxycholic acid	Cap 250 mg	Ursosan	
Vancomycin	Inj 500 mg vial	Mylan	
Zidovudine [AZT] with lamivudine	Tab 300 mg with lamivudine 150 mg	Alphapharm	

* no subsidy changes for these brands for 1 July 2017.